Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

During the Trading Day
2.12 +0.11 / +5.47%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
2.03 -0.09 / -4.25%
 
Volume: 9.1K
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$8.3M

Company Description

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of monoclonal antibody therapeutics. It develops a portfolio of proprietary and patient-targeted monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer. The company's antibody technology, Humaneered, treats serious medical conditions with a primary clinical focus on respiratory diseases and cancer. KaloBios Pharmaceuticals was founded on March 15, 2000 and is headquartered in South San Francisco, CA.

Contact Information

KaloBios Pharmaceuticals, Inc.
442 Littlefield Avenue
South San Francisco California 94080
P:(650) 243-3100
Investor Relations:

Employees

Shareholders

Other institutional6.76%
Mutual fund holders14.30%
Individual stakeholders--

Top Executives

Herbert C. CrossChief Executive & Financial Officer
Geoffrey Thomas YarrantonChief Scientific Officer
Harry LamSenior Vice President-Technical Operations
Anne Borgman HageyAssociate Chief Medical Officer
Donald R. JosephSecretary & Chief Legal Officer